Related Experiment Video
Updated: Jul 16, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Survival and Economic Benefits of Implementing Evidence-Based Tobacco Treatment Across US Cancer Care
George Kypriotakis1, Francesco Versace1, Maher Karam-Hage1
1Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX.
Purpose:
Continued smoking after a cancer diagnosis worsens survival and increases health care costs. We projected the 10-year survival gains and health care cost savings associated with nationwide implementation of evidence-based tobacco treatment for US patients with cancer and survivors.
Methods:
We developed a population-based dynamic survival and cost model including 18 million US cancer survivors, assuming 11.4% smoking prevalence, and 2 million annual incident cancer cases, assuming 15% smoking prevalence. The model tracked annual transitions among smoking, abstinence, relapse, survival, and death over 10 years, using proportional hazards survival mapping, explicit relapse dynamics, and 3% annual cost discounting. The primary comprehensive program scenario assumed 50% program reach, 45% abstinence among reached patients, a mortality hazard ratio of 0.79 for abstainers versus continuing smokers, and 20% annual relapse. Implementation scenarios and probabilistic sensitivity analyses were evaluated.
Results:
The comprehensive program scenario was projected to prevent 66,462 deaths and yield 287,446 life-years gained over 10 years, with $12.32 billion US dollars (USD) in present-value (PV) health care cost savings. In probabilistic sensitivity analysis with 10,000 simulations, mean outcomes were 66,542 lives saved (95% uncertainty interval [UI], 28,394 to 116,297) and $12.38 billion USD in PV cost savings (95% UI, $6.95 to $20.69 billion USD). An enhanced implementation scenario with 80% reach and 60% abstinence was projected to prevent 141,785 deaths, yield 613,219 life-years gained, and save $26.28 billion USD. Reach, abstinence, and relapse were the primary drivers of survival and economic value. The break-even program cost per participant was approximately $5,255 USD.
Conclusion:
National implementation of evidence-based tobacco treatment in cancer care could save tens of thousands of lives and substantially reduce health care costs within 10 years.
Related Concept Videos
Cancer Survival Analysis
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Statistical Methods for Analyzing Epidemiological Data